Zymeworks downgraded to Neutral from Buy at Citi. Citi analyst Yigal Nochomovitz downgraded Zymeworks to Neutral while raising his price target for the shares to $20 from $18. The analyst believes the good ZW25 data at ASCO are now reflected in the valuation. Further, he sees a lack of near-term share catalysts
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.